EN-US Sat, 25 May 2013 00:42:17 -0400 130403 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qPTQ_GN0sbU/mixed-data-on-mercks-vorapaxar-analyst-blog-cm130403 Investing Business Stocks Merck's ( MRK ) vorapaxar was in the news recently with researchers presenting detailed results on the candidate from the TRA-2P (Thrombin-Receptor Antagonist in Secondary Prevention of<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/qPTQ_GN0sbU" height="1" width="1"/> Thu, 29 Mar 2012 00:22:46 Z 2012-03-28T22:17:08Z Zacks Equity Research AZN BMY CV ICH LLY http://www.nasdaq.com/article/mixed-data-on-mercks-vorapaxar-analyst-blog-cm130403 119509 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YbCO3nt2ZYk/higher-bleeding-haunts-merck-candidate-analyst-blog-cm119509 Investing Business Stocks Merck ( MRK ) recently announced top-line data on its anti-clotting candidate, vorapaxar, from the TRA-2P (Thrombin Receptor Antagonist in Secondary Prevention of atherothrombotic<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/YbCO3nt2ZYk" height="1" width="1"/> Thu, 09 Feb 2012 01:00:01 Z 2012-02-08T22:07:29Z Zacks Equity Research AZN BMY ICH LLY MRK http://www.nasdaq.com/article/higher-bleeding-haunts-merck-candidate-analyst-blog-cm119509